Find out how Phinomics is using circular DNA and explainable AI to reshape oncology discovery and cancer biomarker research.…
Could Phinomics’ circular DNA platform expose the blind spots slowing cancer drug development?
Volta Labs and Twist Bioscience push target enrichment closer to walk-away automation
Read how Volta Labs’ Twist Fast Hyb launch on Callisto could reshape automated NGS target enrichment, lab throughput and sequencing workflows.…
Why Medtronic’s Scientia Vascular acquisition matters for stroke device workflows
Find out how Medtronic’s Scientia Vascular acquisition could reshape neurovascular access, stroke workflows and medtech competition.…
Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
Find out how Simcere and Stanford Medicine’s IPF collaboration could reshape early-stage antifibrotic drug discovery.…
Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention
Read how Acousia Therapeutics’ bimokalner Phase 2a signal could reshape cisplatin hearing loss prevention in adults.…
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.…
Is Lateral Pharma’s pain platform quietly opening a new biotech battleground?
Find out how Lateral Pharma’s LanCL1 discovery could reshape neuropathic pain drug research and open a new biotech opportunity.…
Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.…
Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access
Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.…
Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk
Find out how Amgen’s Tavneos data review could shape FDA withdrawal risk, liver safety scrutiny, and ANCA vasculitis care.…
Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus
Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.…
Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.…
Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment
Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.…
Volta Labs and Twist Bioscience push target enrichment closer to walk-away automation
Why Medtronic’s Scientia Vascular acquisition matters for stroke device workflows
Baxter faces FDA early alert as Volara circuit leakage risk threatens respiratory care
